Paper Details

  1. Home
  2. Paper Details

Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center.

Author: CefaliFrank, FentonRebecca, SulicaRoxana

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are rare, life-threatening diseases in which chronically elevated pressure in the pulmonary arteries results in vascular remodeling and right heart failure. Treatment goals are to improve patient functioning, exercise capacity, and symptoms; delay disease progression; normalize the right ventricular function; and, ultimately, improve survival. Riociguat, a novel therapeutic agent that stimulates soluble guanylate cyclase via the nitric oxide pathway, was approved for the treatment of both PAH and CTEPH.
Paper Details　
Original Abstract of the Article :
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are rare, life-threatening diseases in which chronically elevated pressure in the pulmonary arteries results in vascular remodeling and right heart failure. Treatment goals are to improve patient function...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675747/

データ提供：米国国立医学図書館（NLM）

Riociguat: A New Hope for Pulmonary Arterial Hypertension

Navigating the [desert of pulmonary arterial hypertension (PAH)] can be a daunting journey, with limited treatment options and a high risk of [right heart failure]. This study explores the potential of [riociguat] as a novel therapeutic agent for both [PAH] and [chronic thromboembolic pulmonary hypertension (CTEPH)]. The researchers investigated the [efficacy] of [riociguat] in a large treatment center, evaluating its impact on [exercise capacity], [hemodynamic parameters], and overall [disease progression].

Riociguat: A New Weapon Against PAH

This research presents [riociguat] as a promising new weapon in the fight against [PAH] and [CTEPH]. The study findings indicate that [riociguat] significantly improves [exercise capacity] and [hemodynamic parameters] in patients with [PAH/CTEPH], demonstrating its potential to [delay disease progression] and [improve quality of life]. This discovery offers new hope for patients facing the challenges of these debilitating conditions.

Exploring New Horizons in PAH Treatment

The [desert of PAH treatment] has historically been a barren landscape with limited options. This study brings a glimmer of hope by showcasing the potential of [riociguat] as a [novel therapeutic agent]. Its [efficacy] in improving [exercise capacity] and [hemodynamic parameters] suggests that it could offer a significant improvement in the lives of patients with [PAH/CTEPH]. This research encourages further exploration of [riociguat] and its potential to revolutionize [PAH/CTEPH] treatment.

Dr.Camel's Conclusion

Like an oasis in the vast desert of PAH, riociguat offers a promising new treatment option. The study highlights its potential to improve exercise capacity, hemodynamic parameters, and overall disease progression, offering hope for a brighter future for patients. Let's continue to explore this oasis and unlock its full potential.

Date :
  1. Date Completed 2015-12-15
  2. Date Revised 2020-09-30
Further Info :

Pubmed ID

26411969

DOI: Digital Object Identifier

PMC4675747

Related Literature

Article Analysis
・Side Effects of riociguat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.